TN2015000019A1 - Prediction of treatment response to jak/stat inhibitor - Google Patents

Prediction of treatment response to jak/stat inhibitor

Info

Publication number
TN2015000019A1
TN2015000019A1 TNP2015000019A TN2015000019A TN2015000019A1 TN 2015000019 A1 TN2015000019 A1 TN 2015000019A1 TN P2015000019 A TNP2015000019 A TN P2015000019A TN 2015000019 A TN2015000019 A TN 2015000019A TN 2015000019 A1 TN2015000019 A1 TN 2015000019A1
Authority
TN
Tunisia
Prior art keywords
jak
prediction
stat inhibitor
treatment response
stat
Prior art date
Application number
TNP2015000019A
Other languages
English (en)
French (fr)
Inventor
Alexander Cao
Michael Morrissey
Dmitriy Sonkin
Michael Palmer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2015000019A1 publication Critical patent/TN2015000019A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TNP2015000019A 2012-07-27 2015-01-16 Prediction of treatment response to jak/stat inhibitor TN2015000019A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676484P 2012-07-27 2012-07-27
US201361769271P 2013-02-26 2013-02-26
US201361829327P 2013-05-31 2013-05-31
PCT/US2013/051824 WO2014018632A1 (en) 2012-07-27 2013-07-24 Prediction of treatment response to jak/stat inhibitor

Publications (1)

Publication Number Publication Date
TN2015000019A1 true TN2015000019A1 (en) 2016-06-29

Family

ID=48906529

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2015000019A TN2015000019A1 (en) 2012-07-27 2015-01-16 Prediction of treatment response to jak/stat inhibitor

Country Status (18)

Country Link
US (1) US20150299796A1 (cg-RX-API-DMAC7.html)
EP (1) EP2877596A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015526074A (cg-RX-API-DMAC7.html)
KR (1) KR20150038241A (cg-RX-API-DMAC7.html)
CN (1) CN104508149A (cg-RX-API-DMAC7.html)
AU (2) AU2013295855A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015001521A2 (cg-RX-API-DMAC7.html)
CA (1) CA2880198A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000192A1 (cg-RX-API-DMAC7.html)
HK (1) HK1205198A1 (cg-RX-API-DMAC7.html)
IL (1) IL236897A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015001269A (cg-RX-API-DMAC7.html)
PH (1) PH12015500169A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015106714A (cg-RX-API-DMAC7.html)
SG (1) SG11201500261VA (cg-RX-API-DMAC7.html)
TN (1) TN2015000019A1 (cg-RX-API-DMAC7.html)
TW (1) TW201409030A (cg-RX-API-DMAC7.html)
WO (1) WO2014018632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106544414A (zh) * 2016-10-09 2017-03-29 广州泰诺迪生物科技有限公司 一种检测肺癌脑转移样本中stat3和lck的方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107137701B (zh) * 2017-05-07 2020-07-14 山东兴瑞生物科技有限公司 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US20060194275A1 (en) * 2001-04-13 2006-08-31 Incyte Corporation Transporter and ion channels
JP2012506238A (ja) * 2008-10-20 2012-03-15 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト インスリン様増殖因子−1受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー
WO2010141796A2 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
EA201390815A1 (ru) * 2010-12-03 2013-12-30 Им Байосайенсиз Острелиа Пти Лтд. Лечение jak2-опосредованных состояний

Also Published As

Publication number Publication date
TW201409030A (zh) 2014-03-01
EP2877596A1 (en) 2015-06-03
MX2015001269A (es) 2015-05-08
US20150299796A1 (en) 2015-10-22
CN104508149A (zh) 2015-04-08
RU2015106714A (ru) 2016-09-20
BR112015001521A2 (pt) 2017-11-07
AU2017204894A1 (en) 2017-08-03
KR20150038241A (ko) 2015-04-08
IL236897A0 (en) 2015-03-31
AU2013295855A1 (en) 2015-02-12
WO2014018632A1 (en) 2014-01-30
PH12015500169A1 (en) 2015-03-16
CA2880198A1 (en) 2014-01-30
HK1205198A1 (en) 2015-12-11
JP2015526074A (ja) 2015-09-10
CL2015000192A1 (es) 2015-06-26
SG11201500261VA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
PH12015502075B1 (en) Treatment of cataplexy
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
NZ630542A (en) Methods of treating a tauopathy
EP3076977A4 (en) Combination therapy for treating cancer
PH12015502091A1 (en) Cdc7 inhibitors
LT3033086T (lt) Kombinuota terapija vėžiui gydyti
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PH12015502042B1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
EA201590359A1 (ru) Лечение ревматоидного артрита
WO2014151606A3 (en) Methods of treating pancreatic cancer
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
LT2825558T (lt) Derinių terapija, skirta kiaušidžių vėžiui gydyti
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
PH12017500923A1 (en) New dosage and use of a a2a antagonist
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
IN2014KN01772A (cg-RX-API-DMAC7.html)
MX350868B (es) Medicamentos y metodos para tratar cancer.
UA88729U (uk) Спосіб консервативного лікування хронічного геморою